Drug Development Consulting BidCo ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 4.0% 2.4% 3.0%  
Credit score (0-100)  0 0 48 63 56  
Credit rating  N/A N/A BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.8 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -4,389 3,760 2,320  
EBITDA  0.0 0.0 -5,320 1,822 -622  
EBIT  0.0 0.0 -5,320 1,822 -622  
Pre-tax profit (PTP)  0.0 0.0 -16,103.0 -12,568.0 -10,330.0  
Net earnings  0.0 0.0 -15,752.0 -11,831.0 -9,381.0  
Pre-tax profit without non-rec. items  0.0 0.0 -16,103 -12,568 -10,330  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 70,809 71,831 70,212  
Interest-bearing liabilities  0.0 0.0 107,500 51,030 48,310  
Balance sheet total (assets)  0.0 0.0 129,982 124,307 120,669  

Net Debt  0.0 0.0 105,606 34,350 46,893  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -4,389 3,760 2,320  
Gross profit growth  0.0% 0.0% 0.0% 0.0% -38.3%  
Employees  0 0 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 129,982 124,307 120,669  
Balance sheet change%  0.0% 0.0% 0.0% -4.4% -2.9%  
Added value  0.0 0.0 -5,320.0 1,822.0 -622.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 1.0 -1.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 121.2% 48.5% -26.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -11.3% -7.8% -5.3%  
ROI %  0.0% 0.0% -11.5% -7.9% -5.4%  
ROE %  0.0% 0.0% -22.2% -16.6% -13.2%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 54.5% 57.8% 58.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -1,985.1% 1,885.3% -7,539.1%  
Gearing %  0.0% 0.0% 151.8% 71.0% 68.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 2.7% 3.4% 7.7%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.8 4.3 1.6  
Current Ratio  0.0 0.0 0.8 4.3 1.6  
Cash and cash equivalent  0.0 0.0 1,894.0 16,680.0 1,417.0  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -1,035.0 13,831.0 3,060.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -5,320 1,822 -622  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -5,320 1,822 -622  
EBIT / employee  0 0 -5,320 1,822 -622  
Net earnings / employee  0 0 -15,752 -11,831 -9,381